Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

Panelists discuss how the approval of afamitresgene autoleucel (afami-cel) as the first T-cell receptor (TCR) therapy marks a pivotal milestone that could accelerate development and acceptance of TCR-based treatments by establishing regulatory precedent, validating the therapeutic approach, and providing real-world evidence of safety and efficacy in solid tumors.